1. Dipòsit Digital de la Universitat de Barcelona
  2. Recerca
  3. Economia
  4. Articles publicats en revistes (Economia)
Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/107753
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDarbà, Josep-
dc.contributor.authorRamírez, Gabriela-
dc.contributor.authorGarcía-Rivero, Juan L.-
dc.contributor.authorMayoralas, Sagrario-
dc.contributor.authorPascual, José Francisco-
dc.contributor.authorRoger, Albert-
dc.contributor.authorVargas, Diego-
dc.contributor.authorBijedic, Adi-
dc.date.accessioned2017-03-02T15:37:24Z-
dc.date.available2017-03-02T15:37:24Z-
dc.date.issued2016-09-
dc.identifier.issn1178-6981-
dc.identifier.urihttp://hdl.handle.net/2445/107753-
dc.description.abstractTo assess the economic impact of the introduction of DuoResp(®) Spiromax(®) by focusing on a potential improvement in the inhalation technique to strengthen medication adherence for the treatment of moderate to severe asthmatics in Spain and five Spanish regions including Andalusia, Catalonia, Galicia, Madrid, and Valencia. ...-
dc.format.extent10 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherDove Medical Press-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.2147/CEOR.S111453-
dc.relation.ispartofClinicoeconomics and Outcomes Research, 2016, vol. 8 , p. 435-444-
dc.relation.urihttps://doi.org/10.2147/CEOR.S111453-
dc.rightscc-by-nc (c) Darbà, Josep et al., 2016-
dc.rights.urihttp://creativecommons.org/licenses/by-nc/3.0/es-
dc.sourceArticles publicats en revistes (Economia)-
dc.subject.classificationAdministració de medicaments-
dc.subject.classificationAsma-
dc.subject.classificationMalalties pulmonars obstructives cròniques-
dc.subject.classificationTractament tèrmic-
dc.subject.classificationEconomia de la salut-
dc.subject.otherAdministration of drugs-
dc.subject.otherAsthma-
dc.subject.otherChronic obstructive pulmonary diseases-
dc.subject.otherHeat treatment-
dc.subject.otherMedical economics-
dc.titleA budget impact analysis of Spiromax compared with Turbuhaler for the treatment of moderate to severe asthma: a potential improvement in the inhalation technique to strengthen medication adherence could represent savings for the Spanish Healthcare System and five Spanish regions-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.identifier.idgrec668397-
dc.date.updated2017-03-02T15:37:24Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid27660476-
Appears in Collections:Articles publicats en revistes (Economia)

Files in This Item:
File Description SizeFormat 
668397.pdf270.56 kBAdobe PDFView/Open
Show simple item record


This item is licensed under a Creative Commons License Creative Commons